MAPT and Alzheimer disease: Enhancing glutamatergic neurotransmission has been shown to inhibit the expression of vesicular glutamate transporter 1 in presynaptic vesicles of AD mice, modulate the glutamatergic/GABAergic balance in the hippocampal dentate gyrus, significantly reduce Aβ and tau protein deposition, suppress glutamate release induced by external stimuli, and improve synaptic plasticity, ultimately restoring cognitive function (Shen et al., 2025).